Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2009 1
2010 2
2011 1
2012 1
2013 2
2014 3
2015 3
2016 4
2017 3
2018 9
2019 9
2020 11
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

49 results
Results by year
Filters applied: . Clear all Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators. Lipson DA, et al. N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18. N Engl J Med. 2018. PMID: 29668352 Free article. Clinical Trial.
BACKGROUND: The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting beta(2)-agonist (LABA), as compared with dual therapy (either inhaled glucocorticoid- …
BACKGROUND: The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting mu …
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P; ETHOS Investigators. Rabe KF, et al. N Engl J Med. 2020 Jul 2;383(1):35-48. doi: 10.1056/NEJMoa1916046. Epub 2020 Jun 24. N Engl J Med. 2020. PMID: 32579807 Clinical Trial.
BACKGROUND: Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting beta(2)-agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been studied at single dose levels of inhaled glucocorticoid, but …
BACKGROUND: Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting beta(2)-a …
The Global Initiative for Asthma (GINA): 25 years later.
Boulet LP, Reddel HK, Bateman E, Pedersen S, FitzGerald JM, O'Byrne PM. Boulet LP, et al. Eur Respir J. 2019 Aug 29;54(2):1900598. doi: 10.1183/13993003.00598-2019. Print 2019 Aug. Eur Respir J. 2019. PMID: 31273040 Free article. Review.
Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone.
Stempel DA, Raphiou IH, Kral KM, Yeakey AM, Emmett AH, Prazma CM, Buaron KS, Pascoe SJ; AUSTRI Investigators. Stempel DA, et al. N Engl J Med. 2016 May 12;374(19):1822-30. doi: 10.1056/NEJMoa1511049. Epub 2016 Mar 6. N Engl J Med. 2016. PMID: 26949137 Free article. Clinical Trial.
This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. ...
This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, flut …
Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis.
Cazzola M, Rogliani P, Calzetta L, Matera MG. Cazzola M, et al. Eur Respir J. 2018 Dec 13;52(6):1801586. doi: 10.1183/13993003.01586-2018. Print 2018 Dec. Eur Respir J. 2018. PMID: 30309975 Free article.
The ICS/LABA/LAMA combination reduced the risk of exacerbation (relative risk 0.70, 95% CI 0.53-0.94) and improved trough forced expiratory volume in 1 s (mean difference in mL +37.94, 95% CI 18.83-53.89) versus LABA/LAMA combination therapy. ...This meta-analysis s …
The ICS/LABA/LAMA combination reduced the risk of exacerbation (relative risk 0.70, 95% CI 0.53-0.94) and improved trough forced expi …
Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma.
Stempel DA, Szefler SJ, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, Liu AH, Mitchell H, Kral KM, Raphiou IH, Prillaman BA, Buaron KS, Yun Kirby S, Pascoe SJ; VESTRI Investigators. Stempel DA, et al. N Engl J Med. 2016 Sep 1;375(9):840-9. doi: 10.1056/NEJMoa1606356. N Engl J Med. 2016. PMID: 27579634 Free article. Clinical Trial.
It is unknown whether the concomitant use of inhaled glucocorticoids with LABAs mitigates those risks. This trial prospectively evaluated the safety of the LABA salmeterol, added to fluticasone propionate, in a fixed-dose combination in children. ...
It is unknown whether the concomitant use of inhaled glucocorticoids with LABAs mitigates those risks. This trial prospectively evaluated th …
Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma.
Wechsler ME, Szefler SJ, Ortega VE, Pongracic JA, Chinchilli V, Lima JJ, Krishnan JA, Kunselman SJ, Mauger D, Bleecker ER, Bacharier LB, Beigelman A, Benson M, Blake KV, Cabana MD, Cardet JC, Castro M, Chmiel JF, Covar R, Denlinger L, DiMango E, Fitzpatrick AM, Gentile D, Grossman N, Holguin F, Jackson DJ, Kumar H, Kraft M, LaForce CF, Lang J, Lazarus SC, Lemanske RF Jr, Long D, Lugogo N, Martinez F, Meyers DA, Moore WC, Moy J, Naureckas E, Olin JT, Peters SP, Phipatanakul W, Que L, Raissy H, Robison RG, Ross K, Sheehan W, Smith LJ, Solway J, Sorkness CA, Sullivan-Vedder L, Wenzel S, White S, Israel E; NHLBI AsthmaNet. Wechsler ME, et al. N Engl J Med. 2019 Sep 26;381(13):1227-1239. doi: 10.1056/NEJMoa1905560. N Engl J Med. 2019. PMID: 31553835 Free PMC article. Clinical Trial.
Data indicate that patients with inadequately controlled asthma benefit more from addition of a long-acting beta-agonist (LABA) than from increased glucocorticoids; however, these data may not be informative for treatment in black patients. ...We compared combinations of t …
Data indicate that patients with inadequately controlled asthma benefit more from addition of a long-acting beta-agonist (LABA) than …
SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis.
Rogliani P, Ritondo BL, Ora J, Cazzola M, Calzetta L. Rogliani P, et al. Eur Respir J. 2020 Sep 10;56(3):2000625. doi: 10.1183/13993003.00625-2020. Print 2020 Sep. Eur Respir J. 2020. PMID: 32430423
In adult mild-to-moderate asthmatic patients low-dose SMART and as-needed low-dose ICS/LABA combination were significantly (relative effect <0.78; p<0.05) more effective than the other as-needed therapies in reducing the risk of exacerbation, and both were ranked as …
In adult mild-to-moderate asthmatic patients low-dose SMART and as-needed low-dose ICS/LABA combination were significantly (relative …
A golden age of asthma research.
O'Byrne PM, Pavord ID. O'Byrne PM, et al. Eur Respir J. 2020 Dec 24;56(6):2003820. doi: 10.1183/13993003.03820-2020. Print 2020 Dec. Eur Respir J. 2020. PMID: 33361451 No abstract available.
49 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page